AIM
HEALTHCAREAIM ImmunoTech Inc
AI Insight
What's Moving AIM Today?
No stock-specific AI insight has been generated for AIM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.21$9.76
$0.37
Fundamentals
Market Cap$10M
P/E Ratio—
EPS$-4.31
Dividend Yield—
Dividend / Share—
ROE-3,139.0%
Profit Margin—
Debt / Equity—
Trading
Volume3.3M
Avg Volume (10D)—
Shares Outstanding27.7M
AIM News
20 articles- AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical MilestonesYahoo Finance·Jun 24, 2026
- AIM ImmunoTech to Present in the Webull Corporate Connect Webinar SeriesYahoo Finance·Jun 22, 2026
- AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic CancerYahoo Finance·Jun 18, 2026
- Bet on 5 Top-Ranked Stocks With Rising P/E for Solid ReturnsYahoo Finance·Jun 18, 2026
- AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity DeficiencyYahoo Finance·Jun 15, 2026
- AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American RulesYahoo Finance·Jun 9, 2026
- AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic CancerYahoo Finance·Jun 8, 2026
- AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease PreparednessYahoo Finance·Jun 4, 2026
- AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' AheadStocktwits·Jun 1, 2026
- AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical MilestonesYahoo Finance·Jun 1, 2026
- AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency DeclarationYahoo Finance·May 27, 2026
- AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private PlacementYahoo Finance·May 20, 2026
- AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical PrioritiesYahoo Finance·May 19, 2026
- AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic CancerYahoo Finance·May 14, 2026
- Transcript: Aimia Q1 2026 Earnings Conference CallYahoo Finance·May 13, 2026
- AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross ProceedsYahoo Finance·May 8, 2026
- AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination PotentialYahoo Finance·May 7, 2026
- AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IPYahoo Finance·Apr 16, 2026
- AIM ImmunoTech Provides Routine Update on Annual FilingsGlobeNewswire Inc.·Apr 13, 2026
- AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell EventYahoo Finance·Apr 9, 2026
All 20 articles loaded
Price Data
Open$0.35
Previous Close$0.36
Day High$0.38
Day Low$0.33
52 Week High$9.76
52 Week Low$0.21
52-Week Range
$0.21$9.76
$0.37
Fundamentals
Market Cap$10M
P/E Ratio—
EPS$-4.31
Dividend Yield—
Dividend / Share—
ROE-3,139.0%
Profit Margin—
Debt / Equity—
Trading
Volume3.3M
Avg Volume (10D)—
Shares Outstanding27.7M
About AIM ImmunoTech Inc
AIM ImmunoTech Inc., an immunpharmaceutical company, focuses on research and development of therapies to treat multiple types of cancers, viruses, and immunodeficiency disorders in the United States. The company is headquartered in Ocala, Florida.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeAMEX
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—